PURE Bioscience, Inc. (OTCMKTS:PURE) Sees Large Decrease in Short Interest

PURE Bioscience, Inc. (OTCMKTS:PURE) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 600 shares, a decrease of 98.3% from the February 13th total of 36,200 shares. Based on an average trading volume of 59,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

PURE Bioscience Price Performance

Shares of OTCMKTS PURE traded up $0.01 during trading hours on Wednesday, reaching $0.05. The stock had a trading volume of 81,222 shares, compared to its average volume of 60,121. The business’s fifty day moving average is $0.07 and its two-hundred day moving average is $0.08. PURE Bioscience has a twelve month low of $0.05 and a twelve month high of $0.16. The company has a market cap of $5.87 million, a price-to-earnings ratio of -1.31 and a beta of 0.35.

PURE Bioscience (OTCMKTS:PURE) last announced its quarterly earnings data on Monday, December 16th. The company reported ($0.01) earnings per share (EPS) for the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.